Join us to explore pioneering projects from MIT’s Senseable City Lab, a multidisciplinary research group transforming urban living worldwide. From urban mobility and biodiversity to environmental quality and community well-being, the presentation showcases how digital technologies are reshaping cities at every scale—from individual buildings to entire metropolises.
This webinar provides invaluable perspectives for anyone dedicated to creating smarter, more livable cities.
P&G is looking for solutions that can become ongoing sources of first party shopping data.
Jan Schnorr, CEO, C2Sense
Speak at 2023 MIT Digital Technology and Strategy Conference - Startup Lightning Talks and Lunch Exhibit - Oct 25.
MIT Startup Exchange presents its September Startup Workshop, centered around real-world IoT and edge computing. Many companies are grappling with how to use IoT and data/AI in their organization to monitor, predict, improve, and transform what they do. Meanwhile, many MIT startups are developing and providing innovative technology solutions to answer these very questions for industry. This workshop will present perspectives from industry leaders, academics, and corporate investors, while also showcasing select MIT startups in the field.
CSC Leasing x venˣ Fireside Chat + Happy Hour at The Engine!
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.